Inhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe Buys 26,963 Shares

Inhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe acquired 26,963 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were purchased at an average cost of $15.05 per share, for a total transaction of $405,793.15. Following the completion of the transaction, the chief executive officer now directly owns 692,511 shares in the company, valued at approximately $10,422,290.55. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Mark Lappe also recently made the following trade(s):

• On Monday, September 16th, Mark Lappe bought 13,037 shares of Inhibrx stock. The stock was purchased at an average price of $17.13 per share, for a total transaction of $223,323.81.
• On Monday, September 9th, Mark Lappe purchased 9,500 shares of Inhibrx stock. The shares were purchased at an average cost of $15.21 per share, with a total value of $144,495.00.
• On Friday, September 6th, Mark Lappe acquired 26,000 shares of Inhibrx stock. The stock was acquired at an average cost of $15.29 per share, for a total transaction of $397,540.00.
• On Tuesday, September 3rd, Mark Lappe purchased 20,000 shares of Inhibrx stock. The stock was acquired at an average price of $15.81 per share, with a total value of $316,200.00.
• On Thursday, August 29th, Mark Lappe bought 10,000 shares of Inhibrx stock. The stock was acquired at an average cost of $14.03 per share, with a total value of $140,300.00.

Inhibrx Trading Down 1.3 %

Shares of INBX opened at $16.99 on Thursday. Inhibrx, Inc. has a 1-year low of $10.80 and a 1-year high of $18.95. The firm has a fifty day simple moving average of $13.87 and a two-hundred day simple moving average of $23.42.

Inhibrx (NASDAQ:INBX) last issued its quarterly earnings results on Tuesday, August 13th. The company reported $125.48 earnings per share for the quarter, topping the consensus estimate of ($3.60) by $129.08. The business had revenue of $0.10 million for the quarter. As a group, analysts forecast that Inhibrx, Inc. will post 87.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, JMP Securities began coverage on shares of Inhibrx in a research note on Tuesday, July 23rd. They issued a “market perform” rating for the company.

Institutional Trading of Inhibrx

Hedge funds have recently bought and sold shares of the stock. Quadrant Capital Group LLC bought a new position in shares of Inhibrx in the fourth quarter worth about $26,000. Hennion & Walsh Asset Management Inc. increased its holdings in Inhibrx by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 30,561 shares of the company’s stock worth $1,068,000 after acquiring an additional 744 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Inhibrx by 8.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,812 shares of the company’s stock worth $518,000 after acquiring an additional 1,112 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Inhibrx by 7.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,920 shares of the company’s stock valued at $766,000 after purchasing an additional 1,426 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in Inhibrx by 8.5% during the first quarter. Swiss National Bank now owns 42,000 shares of the company’s stock valued at $1,468,000 after purchasing an additional 3,300 shares in the last quarter. Institutional investors own 82.46% of the company’s stock.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.